A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

NCT00874328 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

74

Enrollment

OTHER_GOV

Sponsor class

Conditions

Advanced Non-Small Cell Lung Cancer

Interventions

DRUG: Irinotecan
DRUG: Cisplatin
DRUG: TS-1 (S-1)

Sponsor

National Cancer Center, Korea

Collaborators

[object Object]